Dr Quenet presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the PRODIGE 7 trial.

This was a phase III randomised trial in which patients with stage IV non-metastatic colorectal cancer received surgical treatment with or without heated oxaliplatin chemotherapy.

Dr Quenet describes the median overall survival at 64 months in both groups as equal, the time to disease recurrence as similar and that the addition of chemotherapy doubled the rate of complications.

For more on these results, watch his interview with ecancer, or read news coverage here.

View the slides here.